Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SusmedTSE:4263 59 3-1 Month Momentum % is 3.48% as of Sep. 01, 2026. GuruFocus rates TSE:4263 with a GF Score™ of 59/100 and a GF Value™ of 円904.15 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 675 Healthcare Providers & Services companies, Susmed ranks better than 65.48% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-01), Susmed's 3-1 Month Momentum % is 3.48%.
The industry rank for Susmed's 3-1 Month Momentum % or its related term are showing as below:
TSE:4263's 3-1 Month Momentum % is ranked better than 65.48% of 675
companies
in the Healthcare Providers & Services industry
Industry Median: -2
vs TSE:4263: 3.48
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Susmed 3-1 Month Momentum % Related Terms
TSE:4263 vs VEEV, BTSG, TEM: 3-1 Month Momentum % Comparison
For the Health Information Services subindustry, Susmed's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Susmed 3-1 Month Momentum % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Susmed's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Susmed's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Susmed (TSE:4263) has a 3-1 Month Momentum % of 3.48% as of Sep. 01, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Susmed and its competitors. According to the industry distribution chart, Susmed ranks #233 out of 675 companies in the Healthcare Providers & Services industry, placing it in the top 34.5%.
Is Susmed's 3-1 Month Momentum % too high?
Susmed's current 3-1 Month Momentum % is 3.48%. Based on the distribution chart, Susmed ranks #233 out of 675 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Susmed has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Susmed's 3-1 Month Momentum % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Susmed ranks #233 out of 675 companies for 3-1 Month Momentum %. This puts Susmed in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Healthcare Providers & Services company?
A good 3-1 Month Momentum % depends on the Healthcare Providers & Services industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Susmed and its competitors. Susmed's current 3-1 Month Momentum % is 3.48%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Susmed stock overvalued right now?
Based on GuruFocus' analysis, Susmed (TSE:4263) is currently considered Possible Value Trap. The stock's GF Value™ is 円904.15, compared to a current price of 円454.00 — trading 49.8% below its estimated fair value. The current 3-1 Month Momentum % is 3.48%. Susmed's overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Susmed (TSE:4263), the current 3-1 Month Momentum % is 3.48% as of Sep. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Susmed (TSE:4263) Overvalued in 2026?
Based on GuruFocus' analysis, Susmed stock appears to be undervalued.
The current stock price of 円454.00 is trading 49.8% below its estimated GF Value™ of 円904.15.
GuruFocus considers Susmed to be Possible Value Trap.
Key valuation signals for TSE:4263:
3-1 Month Momentum %: 3.48%
GF Value™: 円904.15 vs. price of 円454.00 (49.8% below fair value)
No single metric tells the full story. See the TSE:4263 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Susmed Inc is engaged in the development of therapeutic smartphone apps and digital solutions to streamline clinical trials. It is currently developing therapeutic apps for patients with insomnia, breast cancer, kidney disease, and other conditions. In addition, it has developed Susumed System, which uses a proprietary blockchain technology to ensure the reliability of clinical trial data, and can reduce the manpower and costs allocated to clinical trials. The company's reportable segments are: the DTx Product Business, which derives maximum revenue, and consists of the development of therapeutic apps; and the DTx Platform Business, which provides general-purpose clinical trial systems and machine learning automated analysis systems.
59GF Score
Get the complete analysis for TSE:4263
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4263 has been successfully added to your 
